This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Does Cobenfy Have the Potential to Become a Top Drug for BMY?
by Ekta Bagri
BMY's Cobenfy gains traction with $155M in 2025 sales, outpacing peers and showing strong uptake as Bristol Myers eyes new indications and growth.
BMYPositive Net Change ABBVPositive Net Change RVPHPositive Net Change
biotechnology biotechs medical pharmaceuticals
BDTX: What Silevertinib Data Say About EGFR NSCLC Upside
by Ekta Bagri
BDTX bets on silevertinib's broad EGFR mutation reach and CNS activity, but with no approved products, upcoming 2026 data and partnerships are pivotal.
AZNPositive Net Change JNJPositive Net Change BDTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Expands Oncology Pipeline With $5B Tubulis Deal
by Zacks Equity Research
Gilead's $5B Tubulis deal expands its ADC pipeline, boosting oncology ambitions as the company accelerates strategic acquisitions beyond HIV.
BIIBPositive Net Change LLYPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know
by Zacks Equity Research
AC Immune stock gains after expansion of its agreement with LLY, adding next-generation Tau Morphomer candidates and boosting long-term Alzheimer's strategy.
LLYPositive Net Change ACIUNegative Net Change INDVPositive Net Change
biotechs
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why
by Zacks Equity Research
SLNO shares surge as Neurocrine inks $2.9B cash deal to acquire it at $53 a share, adding Vykat XR and expanding its rare disease and endocrinology portfolio.
NBIXPositive Net Change INDVPositive Net Change
biotechs
Insmed Ends Brinsupri Development in Skin Disease Post Study Failure
by Zacks Equity Research
INSM scraps Brinsupri for HS after phase IIb failure, with placebo outperforming treatment despite no safety issues.
INSMNegative Net Change ANIPNegative Net Change
biotechs medical
Denali Stock Falls as Partner Takeda Ends Collaboration Deal
by Zacks Equity Research
DNLI's shares decline after Takeda exits DNL593 partnership, leaving Denali to fully control and fund the therapy as it advances studies and plans 2026 data release.
SNYNegative Net Change BIIBPositive Net Change DNLINegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
SNY's Lunsekimig Succeeds in Asthma & CRSwNP Studies, Fails in Eczema
by Zacks Equity Research
Sanofi posts strong mid-stage results for lunsekimig in asthma and CRSwNP but a setback in atopic dermatitis clouds the broader clinical picture.
SNYNegative Net Change ANIPNegative Net Change INDVPositive Net Change
biotechs
Can Corning's Enhanced Healthcare Portfolio Boost Its Shares?
by Zacks Equity Research
GLW powers healthcare innovation with advanced glass, lab tools and bioprocess solutions, driving research, drug safety and scalable biologics production.
APHNegative Net Change GLWNegative Net Change TELPositive Net Change
biotechnology biotechs communications computers tech-stocks
AMGN's Subcutaneous Tepezza Scores Phase III Win in Thyroid Eye Disease
by Zacks Equity Research
Amgen's subcutaneous Tepezza hits phase III goals in thyroid eye disease, matches IV efficacy and offers faster dosing that could expand access.
AMGNPositive Net Change ANIPNegative Net Change VRDNPositive Net Change
biotechs medical pharmaceuticals